ReviewIntegrative medicine (Encinitas, Calif.)2015
Part 2: Treatments for Chronic Gastrointestinal Disease and Gut Dysbiosis.
Review in Integrative medicine (Encinitas, Calif.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Fecal microbiota transplantation in irritable bowel syndrome: A meta-analysis of randomized controlled trials.Frontiers in medicine · 2022Pooled it
- Trial
- Effects ofTropical medicine and infectious disease · 2026Article
- Physiological Mechanisms of and Therapeutic Approaches to the Gut Microbiome and Low-Grade Inflammation in Obesity.Current issues in molecular biology · 2025Review
- The role of microbiome dysbiosis in cardiovascular disease: Mechanisms and therapeutic implications.Global cardiology science & practice · 2025Review
- Healthy microbiome-moving towards functional interpretation.GigaScience · 2025Article
- Unveiling roles of beneficial gut bacteria and optimal diets for health.Frontiers in microbiology · 2025Review
- Review
- Engineering bacterial theranostics: from logic gates toFrontiers in bioengineering and biotechnology · 2024Review
- Article
- Current and Future Therapeutic Options for Irritable Bowel Syndrome with Diarrhea and Functional Diarrhea.Digestive diseases and sciences · 2023Review
- The Role of Probiotics and Their Metabolites in the Treatment of Depression.Molecules (Basel, Switzerland) · 2023Review
- Article
- Effect ofWorld journal of gastroenterology · 2022Article
- The Probiotic VSL#3Pharmaceuticals (Basel, Switzerland) · 2021Article
- Fecal microbiota transplantation for irritable bowel syndrome: An intervention for the 21World journal of gastroenterology · 2021Article
- Novel Therapeutic Strategies for Celiac Disease.Middle East journal of digestive diseases · 2020Review
- Butyrate enhances mitochondrial function during oxidative stress in cell lines from boys with autism.Translational psychiatry · 2018Article
- Evolutionary and ecological forces that shape the bacterial communities of the human gut.Mucosal immunology · 2017Review
- Modulation of Immunological Pathways in Autistic and Neurotypical Lymphoblastoid Cell Lines by the Enteric Microbiome Metabolite Propionic Acid.Frontiers in immunology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Part 1 of this review discussed the connection between the human gut microbiota and health. Manipulation of the intestinal microbiota holds promise as a prospective therapy for gut dysbiosis, ameliorating symptoms of gastrointestinal and systemic diseases and restoring health. The concept of probiotics has existed for more than 100 y, and modern research methods have established sound scientific support for the perceived benefits of probiotic bacteria, which mainly include Lactobacillus and Bifidobacterium genera. On the basis of these evidence-based functional approaches, dietary interventions that supplement the normal diet with probiotics or prebiotics are now considered as potentially viable alternatives or adjuncts to the use of steroids, immunosuppressants, and/or surgical interventions. Studies investigating the impact on gastrointestinal disorders, such as diarrhea, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS); and systemic metabolic diseases, such as type 2 diabetes and obesity, in response to the use of probiotics and prebiotics are reviewed. Further, fecal microbial transplantation (FMT) is discussed as an exciting development in the treatment of gut dysbiosis using microbes.
Identifiers
26770128PMC4566455W2292014584What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.